Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Paragon 28 on Monday, setting a price target of $31, which is approximately 46.71% above the present share price of $21.13.
Matson expects Paragon 28 to post earnings per share (EPS) of $0.00 for the fourth quarter of 2021.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Paragon 28, with an average price target of $29.75.
The analysts price targets range from a high of $31 to a low of $28.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $0 and a net profit of $0. The company's market cap is $1.61 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 13.6% and a 59.36% success rate.
Paragon 28 Inc is a medical devices company that develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Its products include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including ankle, charcot, fracture fixation, hallux valgus, hammertoe, and flatfoot.